MMpH+, a key ingredient used in encapsulating cancer drugs, was found to have new applications in skin care by ITRI researchers. They discovered its benefits in protecting collagen and as a moisturizer to prevent wrinkles, subsequently transferring this technology to DFON Biomedical Technology Inc., the first beauty care startup of ITRI. In early March of 2018, the company officially marked its inauguration and launched the fourth generation anti-aging formula Enzyme Secret AP-I, which provides comprehensive skin protection from the effects of aging, environmental factors, and sun damage.
ITRI Commercialization and Industry Service Center General Director Jia-Ming Liu (third left) and DFON Biomedical Founder and CEO Joshua Lai (third right) at the press conference.
DFON Biomedical Technology Founder and CEO Joshua Lai commented that other skin care products focus on stimulating collagen generation but neglect the importance of decelerating the loss of collagen, which is the key in turning back the skin aging process. DFON’s Enzyme Secret AP-I, he stressed, not only is easily absorbed by the skin, but also can balance MMPs enzymes and key G enzymes, helping to restore the skin’s elasticity and radiance. Working to return luster to the skin, the product also addresses the loss of elastin triggered by damage due to sunlight exposure.
Enzyme Secret serum helps to retain collagen content, and human clinical trials indicate a reduction in the size of pores, along with increased smoothness and tightness in the skin. The appearance of wrinkles is improved and the aging of skin delayed. With its R&D expertise, DFON was selected to enter the Paris&Co business acceleration program. During a six-month trial operation, it sold over 1,000 units of its products. Even Jeanine (Chin Hsi), a Paris-based supermodel, has become a fan of its products. This September DFON’s products are expected to hit the shelves of France’s pharmacy channel.
ITRI Commercialization and Industry Service Center General Director Jia-Ming Liu remarked that ITRI has consistently sought to nurture and incubate startup businesses to commercialize its R&D achievements. In this process, it engages in business planning and investment assessment for these enterprises. DFON, he said, not only is ITRI’s first beauty care startup, but also in 2017 was selected to join Paris&Co, an economic development and innovation agency. With assistance from the French government, participants in Paris&Co have the opportunity to forge business relationships with and earn support from major corporations and venture capital banks in France, he said.
According to ITRI’s Industrial Economics and Knowledge Center, a Euromonitor report shows that the global beauty and personal care market, which stood at NT$426 billion in 2015, is expected to expand to over NT$546.5 billion in 2020, with a compound annual growth of 5.1%. Local cosmetics brands have also increasingly taken root in recent years. As statistics from the Ministry of Economic Affairs show, Taiwan’s cosmetics product exports hit a new high of US$730 million in 2017, rising 13% over the previous year. This suggests growing international interest in Taiwan’s cosmetics brands and the great potential of companies such as DFON in tapping into the international market.
DFON’s fourth generation anti-aging formula Enzyme Secret AP-I.
MMpH+ is a small molecule hyaluronic acid package material developed by ITRI that was originally used to wrap colorectal cancer agents. This ingredient enabled the drug to be delivered to the cancer cells before the agent was released and thus alleviated concerns of the drug harming healthy body tissue. MMpH+ can inhibit MMP. MMP breaks down the collagen at the dermis layer, and when an individual is unable to replenish collagen fast enough, dermal tissue collapses, resulting in wrinkles. MMpH+ can protect collagen so MMP degradation does not occur, thereby keeping the skin well hydrated and preventing wrinkles. MMpH+ is the key ingredient in DFON’s skin care products, and it has already passed many international tests to verify its efficacy and safety, as well as international equipment inspections.
DFON spun off from ITRI in December 2016 and commenced trial operation in the spring of 2017. The R&D team from DFON was comprised of ITRI’s experts in biotech, formulation, and materials and dermatologist consultants. The guiding principle behind DFON is to create safe and effective products with rigorous scientific research and verification. Over the past two years, DFON has exhibited its product at the annual Cosmetic 360 innovations and solutions exhibition in France. In the future, the company will continue to build on this momentum and tap into resources from Paris&Co to make France its hub from which to branch out into the rest of the world.
DFON presently plans to launch its French cosmeceutical project with its Enzyme Secret AP-I anti-aging serum and anticipates having its products on the shelves of pharmacy channel by this September, following which it will expand its reach to Asia and the Americas through local distributors, demonstrating the R&D capabilities and international competitiveness of Taiwan’s cosmetics and skin care products. More information about DFON is available at: https://www.dermafountain.com.